Sam Brusco, Associate Editor12.05.23
inQB8 Medical Technologies, in partnership with Peijia Medical, announced successful implantation of the MonarQ transcatheter tricuspid valve (TTV) in a patient suffering from torrential tricuspid regurgitation (TR) with no other therapy available to her.
The trans-jugular TTVR procedure was performed on December 1, at the UPenn Presbyterian Medical Center, by cardiac surgeon Professor. Dr. Wilson V. Szeto, interventional cardiologist Dr. Jean Chang MD., echo cardiologist Dr. Roy MD., and the attending anesthesiologist Dr. Thal. Prof. Dr. Fabien Praz from Switzerland, and Lars Sondergaard MD. were in attendance sharing their expertise.
"We successfully implanted the MonarQ TTV in the suitable tricuspid region in this extremely high risk patient. My team and I are grateful and excited to work with Dr. Quadri and his team from inQB8, who provided this very exciting MonarQ TTV implantation therapy option to this patient," said Dr. Wilson Szeto. "Due to multiple risk factors and anatomical restrictions, neither traditional tricuspid valve surgery, nor edge-to-edge transcatheter tricuspid repair were options for this patient. Through careful review and consideration within our team, we determined that TTVR with the MonarQ TTV will alleviate symptoms and provide an improved quality of life for this extremely high risk patient whose only other option would have been hospice. The valve was implanted successfully implanted with a dramatic reduction of her torrential tricuspid regurgitation."
"I am honored and delighted to work with Dr. Wilson Szeto and his team at the UPENN Presbyterian Medical Center in this next chapter of transcatheter valve therapy. The MonarQ TTV has a unique BioDynamic attachment system that utilizes and preserves the heart's natural motion by securing the implant to the native leaflets. The Biodynamic motion distribute systolic loads, and a multilobed atrial disc aids in fixation to the native valve and minimizes paravalvular leak. We are very grateful to the patient and her family for consenting to this new type of valve replacement therapy," said Arshad Quadri, M.D., cardiac surgeon and co-founder, executive chairman, and chief medical officer of inQB8.
"In the past few years, the need for a TTVR solution has become increasingly clear. As Peijia looks to expand its presence globally and build its structural heart portfolio, our combined investment in inQB8 and the MonarQ TTVR technology was a natural choice," said Dr. Michael Zhang, Peijia's chairman and CEO. "The successful FIH MonarQ implantation in USA marks an exciting step in bringing this life-
The trans-jugular TTVR procedure was performed on December 1, at the UPenn Presbyterian Medical Center, by cardiac surgeon Professor. Dr. Wilson V. Szeto, interventional cardiologist Dr. Jean Chang MD., echo cardiologist Dr. Roy MD., and the attending anesthesiologist Dr. Thal. Prof. Dr. Fabien Praz from Switzerland, and Lars Sondergaard MD. were in attendance sharing their expertise.
"We successfully implanted the MonarQ TTV in the suitable tricuspid region in this extremely high risk patient. My team and I are grateful and excited to work with Dr. Quadri and his team from inQB8, who provided this very exciting MonarQ TTV implantation therapy option to this patient," said Dr. Wilson Szeto. "Due to multiple risk factors and anatomical restrictions, neither traditional tricuspid valve surgery, nor edge-to-edge transcatheter tricuspid repair were options for this patient. Through careful review and consideration within our team, we determined that TTVR with the MonarQ TTV will alleviate symptoms and provide an improved quality of life for this extremely high risk patient whose only other option would have been hospice. The valve was implanted successfully implanted with a dramatic reduction of her torrential tricuspid regurgitation."
"I am honored and delighted to work with Dr. Wilson Szeto and his team at the UPENN Presbyterian Medical Center in this next chapter of transcatheter valve therapy. The MonarQ TTV has a unique BioDynamic attachment system that utilizes and preserves the heart's natural motion by securing the implant to the native leaflets. The Biodynamic motion distribute systolic loads, and a multilobed atrial disc aids in fixation to the native valve and minimizes paravalvular leak. We are very grateful to the patient and her family for consenting to this new type of valve replacement therapy," said Arshad Quadri, M.D., cardiac surgeon and co-founder, executive chairman, and chief medical officer of inQB8.
"In the past few years, the need for a TTVR solution has become increasingly clear. As Peijia looks to expand its presence globally and build its structural heart portfolio, our combined investment in inQB8 and the MonarQ TTVR technology was a natural choice," said Dr. Michael Zhang, Peijia's chairman and CEO. "The successful FIH MonarQ implantation in USA marks an exciting step in bringing this life-